Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Info Diabetologie
Erschienen in: Info Diabetologie 4/2017

04.09.2017 | Typ-1-Diabetes | fortbildung

Typ-1-Diabetes

Aktueller Stand und Perspektiven der Inselzell-Xenotransplantation

verfasst von: Prof. Dr. med. Jochen Seißler

Erschienen in: Info Diabetologie | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Es wurden ermutigende Fortschritte in der Entwicklung einer Betazellersatztherapie zur Behandlung bei Typ-1-Diabetes gemacht. Mit neuen Methoden könnte es bald gelingen, die Haupthindernisse für die Xenotransplantation, in diesem Fall von speziell gezüchteten Schweinen zum Menschen, soweit zu überwinden, dass klinische Studien möglich werden. Wie es dann weitergeht, ist aber noch unklar.
Literatur
1.
2.
Nathan DM, Bayless M, Cleary P, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 2013; 62:3976–3986.CrossRefPubMedPubMedCentral
3.
Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H, Dahlqvist S, Clements M, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014;371:1972–1982.CrossRefPubMed
4.
Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S. Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation 2017 18;135:1522–1531.CrossRef
5.
Gruessner AC, Sutherland DE, Gruessner RW. Long-term outcome after pancreas transplantation. Curr Opin Organ Transplant 2012;17:100–105.CrossRefPubMed
6.
Fiorina P, Socci C, Gremizzi C, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabet Care 2005;28:1358–1365.CrossRef
7.
Thompson DM, Meloche M, Ao Z, Paty B, Keown P, Shapiro RJ, Ho S, Worsley D, Fung M, Meneilly G, Begg I, Al Mehthel M, Kondi J, Harris C, Fensom B, Kozak SE, Tong SO, Trinh M, Warnock GL. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation 2011;91:373–378.CrossRefPubMed
8.
Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318–1330.CrossRefPubMed
9.
10.
Rickels MR, Peleckis AJ, Markmann E, Dalton-Bakes C, Kong SM, Teff KL, Naji A. Long-Term Improvement in Glucose Control and Counterregulation by Islet Transplantation for Type 1 Diabetes. J Clin Endocrinol Metab 2016;101:4421–4430.CrossRefPubMed
11.
Reichart B, Niemann H, Chavakis T, Denner J, Jaeckel E, Ludwig B, Marckmann G, Schnieke A, Schwinzer R, Seissler J, Tönjes RR, Klymiuk N, Wolf E, Bornstein SR. Xenotransplantation of porcine islet cells as a potential option for the treatment of type 1 diabetes in the future. Horm Metab Res. 2015;47:31–35.PubMed
12.
Ekser B, Tector AJ, Cooper DK. Progress toward clinical xenotransplantation. Int J Surg 2015;23:197–198.CrossRefPubMed
13.
Motté E, Szepessy E, Suenens K, Stangé G, Bomans M, Jacobs-Tulleneers-Thevissen D, Ling Z, Kroon E, Pipeleers D; Beta Cell Therapy Consortium EU-FP7. Composition and function of macroencapsulated human embryonic stem cell-derived implants: comparison with clinical human islet cell grafts. Am J Physiol Endocrinol Metab 2014;307:E838–846.CrossRefPubMed
14.
Rezania A, Bruin JE, Arora P et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol 2014;32:1121–1133.CrossRefPubMed
15.
Pagliuca FW, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D, Melton DA. Generation of functional human pancreatic β cells in vitro. Cell 2014;159:428–439.CrossRefPubMedPubMedCentral
16.
Rajaei B, Shamsara M, Taha MF, Amirabad LM, Massumi M, Sanati MH. Pancreatic Endoderm-Derived From Diabetic Patient-Specific Induced Pluripotent Stem Cell Generates Glucose-Responsive Insulin-Secreting Cells. J Cell Physiol 2016; doi: 10.1002/jcp.25459.
17.
Vegas AJ, Veiseh O, Gürtler M, Millman JR, Pagliuca FW, Bader AR, Doloff JC, Li J, Chen M, Olejnik K, Tam HH, Jhunjhunwala S, Langan E, Aresta-Dasilva S, Gandham S, McGarrigle JJ, Bochenek MA, Hollister-Lock J, Oberholzer J, Greiner DL, Weir GC, Melton DA, Langer R, Anderson DG. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med 2016;22:306–311.CrossRefPubMedPubMedCentral
18.
19.
Ayala-García MA, Gonzalez-Yebra B, López-Flores AL, Guaní-Guerra E. The Major Histocompatibility Complex in Transplantation. J Transplant 2012;2012:842141.PubMedPubMedCentral
20.
Hering BJ, Wijkstrom M, Graham ML, Hårdstedt M, Aasheim TC, Jie T, Ansite JD, Nakano M, Cheng J, Li W. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med. 2006;12:301–303.CrossRefPubMed
21.
Cardona K, Korbutt GS, Milas Z, Lyon J, Cano J, Jiang W, Bello-Laborn H, Hacquoil B, Strobert E, Gangappa S. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med. 2006;12:304–306.CrossRefPubMed
22.
Shin JS, Kim JM, Kim JS, Min BH, Kim YH, Kim HJ, Jang JY, Yoon IH, Kang HJ, Kim J. Long-Term Control of Diabetes in Immunosuppressed Nonhuman Primates (NHP) by the Transplantation of Adult Porcine Islets. Am J Transplant. 2015;15:2837–2850.CrossRefPubMed
23.
24.
Li S, Flisikowska T, Kurome M, Zakhartchenko V, Kessler B, Saur D, Kind A, Wolf E, Flisikowski K, and Schnieke A. Dual fluorescent reporter pig for Cre recombination: transgene placement at the ROSA26 locus. PLoS One. 2014;9:e102455.CrossRefPubMedPubMedCentral
25.
Kurome M, Kessler B, Wuensch A, Nagashima H, Wolf E. Nuclear transfer and transgenesis in the pig. Methods Mol Biol 2015;1222:37–59.CrossRefPubMed
26.
Fischer K, Kraner-Scheiber S, Petersen B, Rieblinger B, Buermann A, Flisikowska T, Flisikowski K, Christan S, Edlinger M, Baars W, Kurome M, Zakhartchenko V, Kessler B, Plotzki E, Szczerbal I, Switonski M, Denner J, Wolf E, Schwinzer R, Niemann H, Kind A, Schnieke A. Efficient production of multi-modified pigs for xenotransplantation by ‚combineering‘, gene stacking and gene editing. Sci Rep 2016;6:29081.CrossRefPubMedPubMedCentral
27.
Niemann H, Petersen B. The production of multi-transgenic pigs: update and perspectives for xenotransplantation. Transgenic Res 2016;25:361–374.CrossRefPubMed
28.
29.
Phelps CJ, Koike C, Vaught TD, Boone J, Wells KD, Chen SH, Ball S, Specht SM, Polejaeva IA, Monahan JA. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science. 2003;299:411–414.CrossRefPubMed
30.
Thompson P, Badell IR, Lowe M, Cano J, Song M, Leopardi F, Avila J, Ruhil R, Strobert E, Korbutt G. Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function. Am J Transplant. 2011;11:2593–2602.CrossRefPubMedPubMedCentral
31.
Lutz AJ, Li P, Estrada JL, Sidner RA, Chihara RK, Downey SM, Burlak C, Wang ZY, Reyes LM, Ivary B. Double knockout pigs deficient in N-glycolylneuraminic acid and galactose α-1,3-galactose reduce the humoral barrier to xenotransplantation. Xenotransplantation. 2013;20:27–35.CrossRefPubMed
32.
Byrne GW, Du Z, Stalboerger P, Kogelberg H, McGregor CG. Cloning and expression of porcine β1,4 N-acetylgalactosaminyl transferase encoding a new xenoreactive antigen. Xenotransplantation 2014;21:543–554.CrossRefPubMedPubMedCentral
33.
Estrada JL, Martens G, Li P, Adams A, Newell KA, Ford ML, Butler JR, Sidner R, Tector M, Tector J. Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA1/CMAH/β4GalNT2 genes. Xenotransplantation 2015;22:194–202CrossRefPubMedPubMedCentral
34.
Cooper DK, Ekser B, Ramsoondar J, Phelps C, Ayares D. The role of genetically engineered pigs in xenotransplantation research. J Pathol. 2016;238:288–299.CrossRefPubMed
35.
Mohiuddin MM, Singh AK, Corcoran PC, Hoyt RF, Thomas ML 3rd, Lewis BG, Eckhaus M, Reimann KA, Klymiuk N, Wolf E, Ayares D, Horvath KA. One-year heterotopic cardiac xenograft survival in a pig to baboon model. Am J Transplant 2014;14:488–489.CrossRefPubMed
36.
Mohiuddin MM, Singh AK, Corcoran PC, Thomas ML 3rd, Clark T, Lewis BG, Hoyt RF, Eckhaus M, Pierson RN 3rd, Belli AJ, Wolf E, Klymiuk N, Phelps C, Reimann KA, Ayares D, Horvath KA. Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft. Nat Commun 2016;7:11138.CrossRefPubMedPubMedCentral
37.
Fu Y, Lu X, Yi S, Wu J, O’Hara JM, Hawthorne WJ, Hucker K, O’Connell PJ. Selective rejection of porcine islet xenografts by macrophages. Xenotransplantation 2008;15:307–312.CrossRefPubMed
38.
Liu W, Xiao X, Demirci G, Madsen J, Li XC. Innate NK cells and macrophages recognize and reject allogeneic nonself in vivo via different mechanisms. J Immunol 2012;188:2703–2711.CrossRefPubMedPubMedCentral
39.
Yamada K, Sachs DH, DerSimonian H. Direct and indirect recognition of pig class II antigens by human T cells. Transplant Proc 1995;27:258–259.PubMed
40.
Olack BJ, Jaramillo A, Benshoff ND, Kaleem Z, Swanson CJ, Lowell JA, Mohanakumar T. Rejection of porcine islet xenografts mediated by CD4+ T cells activated through the indirect antigen recognition pathway. Xenotransplantation. 2002;9:393–401.CrossRefPubMed
41.
42.
Hara H, Witt W, Crossley T, Long C, Isse K, Fan L, et al. Human dominant-negative class II transactivator transgenic pigs - effect on the human anti-pig T-cell immune response and immune status. Immunology 2013;140:39–46.CrossRefPubMedPubMedCentral
43.
Reyes LM, Estrada JL, Wang ZY, Blosser RJ, Smith RF, Sidner RA, Paris LL, Blankenship RL, Ray CN, Miner AC, Tector M, Tector AJ. Creating class I MHC-null pigs using guide RNA and the Cas9 endonuclease. J Immunol 2014;193:5751–5757.CrossRefPubMed
44.
Klymiuk N, van Buerck L, Bahr A, Offers M, Kessler B, Wuensch A, Kurome M, Thormann M, Lochner K, Nagashima H, Herbach N, Wanke R, Seissler J, Wolf E. Xenografted islet cell clusters from INSLEA29Y transgenic pigs rescue diabetes and prevent immune rejection in humanized mice. Diabetes 2012;61:1527–1532.CrossRefPubMedPubMedCentral
45.
Wolf-van Buerck L, Schuster M, Oduncu FS, Baehr A, Mayr T, Guethoff S, Abicht J, Reichart B, Klymiuk N, Wolf E, Seissler J. LEA29Y expression in transgenic neonatal porcine islet-like cluster promotes long-lasting xenograft survival in humanized mice without immunosuppressive therapy. Sci Rep 2017; 3572.
46.
Lee HS, Lee JG, Yeom HJ, Chung YS, Kang B, Hurh S, Cho B, Park H, Hwang JI, Park JB, Ahn C, Kim SJ, Yang J. The Introduction of Human Heme Oxygenase-1 and Soluble Tumor Necrosis Factor-α Receptor Type I With Human IgG1 Fc in Porcine Islets Prolongs Islet Xenograft Survival in Humanized Mice. Am J Transplant 2016;16:44–57.CrossRefPubMed
47.
Klymiuk, N., Ludwig, B., Seissler, J., Reichart, B. & Wolf, E. Current Concepts of Using Pigs as a Source for Beta-Cell Replacement Therapy of Type 1 Diabetes. Current Molecular Biology Reports 2016;2:73–82.CrossRef
48.
Neufeld T, Ludwig B, Barkai U, Weir GC, Colton CK, Evron Y, Balyura M, Yavriyants K, Zimermann B, Azarov D, Maimon S, Shabtay N, Rozenshtein T, Lorber D, Steffen A, Willenz U, Bloch K, Vardi P, Taube R, de Vos P, Lewis EC, Bornstein SR, Rotem A. The efficacy of an immunoisolating membrane system for islet xenotransplantation in minipigs. PLoS One. 2013;8:e70150.CrossRefPubMedPubMedCentral
49.
Ludwig B, Reichel A, Steffen A, Zimerman B, Schally AV, Block NL, Colton CK, Ludwig S, Kersting S, Bonifacio E, Solimena M, Gendler Z, Rotem A, Barkai U, Bornstein SR. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci U S A 2013;110:19054–19058.CrossRefPubMedPubMedCentral
50.
Spizzo T, Denner J, Gazda L, Martin M, Nathu D, Scobie L, Takeuchi Y. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—Chapter 2a: source pigs—preventing xenozoonoses. Xenotransplantation 2016;23:25–31.CrossRefPubMed
51.
Denner J, Tönjes RR, Takeuchi Y, Fishman J, Scobie L. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—Chapter 5: recipient monitoring and response plan for preventing disease transmission. Xenotransplantation 2016;23:53–59.CrossRefPubMed
52.
53.
Denner J. Recent Progress in Xenotransplantation, with Emphasis on Virological Safety. Ann Transplant. 2016;21:717–727.CrossRefPubMed
54.
Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997;3:282–286.CrossRefPubMed
55.
Paradis K, Langford G, Long Z, Heneine W, Sandstrom P, Switzer WM, Chapman LE, Lockey C, Onions D, Otto E. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 1999;285:1236–1241.CrossRefPubMed
56.
Morozov VA, Wynyard S, Matsumoto S, Abalovich A, Denner J, Elliott R. No PERV transmission during a clinical trial of pig islet cell transplantation. Virus Res 2017;227:34–40.CrossRefPubMed
57.
Yang L, Güell M, Niu D, George H, Lesha E, Grishin D, Aach J, Shrock E, Xu W, Poci J, Cortazio R, Wilkinson RA, Fishman JA, Church G. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science 2015;350:1101–104.CrossRefPubMed
58.
Sautermeister J, Mathieu R, Bogner V. Xenotransplantation-theological-ethical considerations in an interdisciplinary symposium. Xenotransplantation 2015;22:174–182.CrossRefPubMed
59.
Paris W, Jang K, Colsch L, Prus A, Bargainer R, Nour B, Cooper DK. Psychosocial challenges of xenotransplantation: the need for a multidisciplinary, religious, and cultural dialogue. Xenotransplantation 2016;23:335–337.CrossRefPubMed
Metadaten
Titel
Typ-1-Diabetes
Aktueller Stand und Perspektiven der Inselzell-Xenotransplantation
verfasst von
Prof. Dr. med. Jochen Seißler
Publikationsdatum
04.09.2017
Verlag
Springer Medizin
Erschienen in
Info Diabetologie / Ausgabe 4/2017
Print ISSN: 1865-5459
Elektronische ISSN: 2196-6362
DOI
https://doi.org/10.1007/s15034-017-1129-8

Weitere Artikel der Ausgabe 4/2017

Info Diabetologie 4/2017 Zur Ausgabe

Noch mehr Komplikationen nach bariatrischer OP

Kombinierter Eingriff: Hier war’s zu viel des „Guten“

aktuell

Auch orales Insulin kann die Diabeteskontrolle verbessern

aktuell

HbA1c-Sturz mit GLP-1-Analogon als Ursache für Retinopathieprogress

aktuell

Nur schwache Hinweise auf Schutz vor Atherosklerose durch Metformin

journal club

Langes Stillen senkt Herzinfarkt- und Schlaganfallrate bei Mama

aktuell

Der Diabetes mellitus kennt keine Organgrenzen

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft. 

Zu den Praxisempfehlungen
Bildnachweise